Conference Coverage

Colchicine before PCI for acute MI fails to improve major outcomes


 

FROM CRT 2021

Timing might be the issue

However, even if colchicine has a potential benefit in this setting, timing might be a major obstacle, according to Binata Shah, MD, associate director of research for the Cardiac Catheterization Laboratory at New York University.

Dr. Binita Shah, New York University

Dr. Binita Shah

“We have learned from our rheumatology colleagues that peak plasma levels of colchicine are not achieved for at least 1 hour after the full loading dose,” Dr. Shah said. “With us moving so quickly in a primary PCI setting, it is hard to imagine that colchicine would have had time to really kick in and exert its anti-inflammatory effect.”

Indeed, the problem might be worse than reaching the peak plasma level.

“Even though peak plasma levels occur as early as 1 hour after a full loading dose, we see that it takes about 24 hours to really see the effects translate downstream into more systemic inflammatory markers such as CRP and interleukin-6,” she added. If lowering these signals of inflammation is predictive of benefit, than this might be the biggest obstacle to benefit from colchicine in an urgent treatment setting.

Dr. Jenab and Dr. Shah reported no potential conflicts of interest.

Pages

Recommended Reading

Calcium-induced autonomic denervation linked to lower post-op AF
MDedge Cardiology
Left-handed cardiology trainees face unique challenges
MDedge Cardiology
Full-dose anticoagulation reduces need for life support in COVID-19
MDedge Cardiology
Newer iPhones disable implanted defibrillators
MDedge Cardiology
Microthrombi, necrosis seen in COVID-19 hearts on autopsy
MDedge Cardiology
PFO closure reduces migraine: New meta-analysis
MDedge Cardiology
Late-window stroke thrombolysis not linked to clot migration
MDedge Cardiology
DOACs offered after heart valve surgery despite absence of data
MDedge Cardiology
BASILICA technique prevents TAVR-related coronary obstruction in registry study
MDedge Cardiology
Target-lesion failure reduced 2 years after MI with biodegradable stent
MDedge Cardiology